RECEIVED CENTRAL FAX CENTER

DEC U 7 2005

Facsimile Transmittal Sheet

Date	12/07/05		Pages including This Title Page 27			
То	Kevin R. Krue	er		From	Carol J. Cavender	
	U.S. Patent & 1	Frademark Office		Company	The Dow Chemical Company	
Fax	(571) 273-8300 (central fax number)			Sender's Fax	989-636-3237	
Phone	571-272-1284			Sender's Phone	979-238-3581	
Appln. Serial No.	10/717,873			Dow Docket No.	60665B	
Subject:	Response to Final Rejection					
☐ Urgent	☐ For Review	☐ Please Comment	Please Reply	☐ Please Recycle	e Please call to confirm receipt of this facsimile	
Commen	ts:		·			
See attach	ed.					
Dow Informa	ation Classification	······································				
DOW CONFIDENTIAL – Do not share without permission				 □ DOW AGROSCIENCES CONFIDENTIAL – Do not share without permission □ MYCOGEN CONFIDENTIAL – Do not share without permission 		

This message is intended for the use of the party to whom it is addressed. It may contain confidential business information. If you are not the intended recipient or an agent of the recipient, any use of this communication is prohibited. If you have received this communication in error, please notify the sender immediately by calling collect, then immediately destroy this message. Thank you.

Form No. 162-01653-1203XQRP

RECEIVED CENTRAL FAX CENTER

DEC 0 7 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No.

10/717,873

Confirmation No. 9382

Applicant (s) Filed Daniel J. Falla, et al. November 20, 2003

TC/A.U.

1773

Examiner

Kruer, Kevin R

Docket No. Customer No.

60665B 00109

CERTIFICATION OF FACSIMILE TRANSMISSION

I HEREBY CERTIFY THAT THIS PAPER IS BEING FACSIMILE
TRANSMITTED TO THE U.S. PATENT OFFICE ON THE DATE SHOWN
BELOW.

December <u>1</u>, 2005

Carol A. Axtell
Type name of person signing certifigate

CARCA. KALL

DATE OF SIGNATURE

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

RESPONSE

Responsive to the Official Action dated October 19, 2005, please reconsider the claims in view of the arguments presented hereinafter.

No Amendments to the Claims are offered in this paper; therefore, there is no listing of claims.

Remarks begin on page 2 of this paper.

Page 1 of 18